Author(s):
Vanshree G. Rathod, Nandakishor B. Deshmukh, Swati P. Deshmukh
Email(s):
Email ID Not Available
DOI:
10.52711/2231-5659.2025.00064 
Address:
Vanshree G. Rathod¹, Nandakishor B. Deshmukh², Swati P. Deshmukh³
1Department of Pharmaceutics, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
2Department of Pharmacology, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
Poor aqueous solubility remains one of the major challenges in the development of oral pharmaceutical formulations, as it significantly limits the bioavailability of many therapeutic agents. A large proportion of newly discovered drug candidates fall into Biopharmaceutics Classification System (BCS) Class II or IV, where solubility is a critical barrier to effective absorption. Enhancing the bioavailability of poorly soluble drugs is essential to achieve desired therapeutic outcomes, reduce dosing frequency, and improve patient compliance. Numerous formulation strategies have been developed to address this issue, ranging from conventional physical and chemical modifications to advanced nanotechnology-based systems. Physical approaches such as particle size reduction, solid dispersions, and lipid-based formulations aim to improve dissolution rates, while chemical techniques like salt formation and prodrug development enhance solubility through molecular modification. Novel drug delivery systems, including nanoparticles, nanosuspensions, liposomes, and self-emulsifying drug delivery systems (SEDDS), offer promising alternatives by improving both solubility and stability. Despite their advantages, these strategies face limitations related to scalability, stability, and regulatory acceptance. This review provides a comprehensive overview of the current and emerging techniques used to enhance the bioavailability of poorly soluble drugs, with a focus on their mechanisms, advantages, limitations, and potential for clinical translation.
Cite this article:
Vanshree G. Rathod, Nandakishor B. Deshmukh, Swati P. Deshmukh. Advanced Formulation Strategies for Enhancing the Bioavailability of Poorly Soluble Drugs: A Comprehensive Review. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):429-2. doi: 10.52711/2231-5659.2025.00064
Cite(Electronic):
Vanshree G. Rathod, Nandakishor B. Deshmukh, Swati P. Deshmukh. Advanced Formulation Strategies for Enhancing the Bioavailability of Poorly Soluble Drugs: A Comprehensive Review. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):429-2. doi: 10.52711/2231-5659.2025.00064 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-4-14
REFERENCES:
1. Kalepu S, Nekkanti V. Biopharmaceutical classification system and solubility enhancement technologies: An overview. Acta Pharm Sin B. 2021; 11(2):39–49.
2. Khan AW, Kotta S, Ansari SH, Ali J. Formulation development and optimization of solid dispersions to improve solubility of poorly water-soluble drugs. Drug Dev Ind Pharm. 2022; 48(3): 312–26.
3. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on Biopharmaceutics Classification System: Basic approaches and practical applications. Int J Pharm. 2023; 642: 120082.
4. Shah N, Dureja H, Kalra S. Nanoparticle technology for oral drug delivery: Recent advances and future directions. J Control Release. 2022; 348: 282–95.
5. Shaker DS, Albadr AA. A comprehensive insight into solid lipid nanoparticles for enhanced drug delivery. Pharm Res. 2024; 41(2): 220–35.
6. Porter CJ, Trevaskis NL, Charman WN. Lipid-based formulations as enabling technology for poorly water-soluble drugs. Nat Rev Drug Discov. 2007; 6(3): 231–48.
7. Patel A, Shelat P. Lipid-based drug delivery system: A review. J Pharm Sci Biosci Res. 2020; 10(3): 123–30.
8. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010; 62(11): 1607–21.
9. Müller RH, Keck CM. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur J Pharm Biopharm. 2012; 80(1): 1–3.
10. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007; 59(7): 603–16.
11. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006; 23(6): 1144–56.
12. Chen Y, Liu C, Chen Z, Su C, Hageman M, Hussain M, et al. Drug–polymer–water interaction and its implication for the dissolution performance of amorphous solid dispersions. Mol Pharm. 2015; 12(2): 576–89.
13. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007; 12(23–24): 1068–75.
14. Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery—an update. Int J Pharm. 2018; 535(1–2): 379–92.
15. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010; 17(6): 585–94.